FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45.”
Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, announced the initial sale of its revolutionary BaroShear K45 processing system. This novel instrument system is based on the Companys proprietary Ultra Shear Technology platform. The BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD Oil.
Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions.
Almost every year, a contagious outbreak occurs in various regions around the world. In efforts to mitigate their spread, health officials mandate that citizens receive vaccinations. However, despite the immediate access to healthcare in many regions, people are still widely affected by these diseases. For instance, the Democratic Republic of the Congo has been experiencing a massive Ebola outbreak which ultimately led the World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus to declare the Ebola outbreak a public health emergency of international concern. Additionally, the Ebola outbreak can potentially spread across to other global regions. For instance, in 2014, a major Ebola outbreak occurred in the African subcontinent and a traveler flying out of Africa spread the disease to the U.S., causing a public health scare. For these reasons, when global outbreaks like the Ebola epidemic occur, health officials around the world often take extensive measures. For instance, the Centers for Disease Control and Prevention sets up exit screenings at the originating country and then an entry screening at the destination. While screenings can be effective, there is still a chance that the disease can spread and as a result, medical institutions and officials need to be prepared. Moreover, the U.S. experienced its largest measles outbreak earlier in 2019, affecting a reported 695 people. However, officials were able to limit the number of deaths due to immunizations and vaccines. Overall, the occurrence of these outbreaks has led many biotechnology companies to accelerate their pipelines and develop more effective treatments. According to data compiled by Global Market Insights, the global biotechnology market was valued at USD 399.4 Billion in 2017. Additionally, by 2024, the market is forecast to surpass USD 775 Billion while registering a CAGR of 9.9% from 2018 to 2024.
While these outbreaks are a major public concern, there is also a large demand for therapies and drugs to treat cases that aren’t contagious. Specifically, conditions such as cancer, autoimmunity/inflammation, infectious agents, and genetic disorders impact a significant number of people each year. In particular, cancer has a huge impact on society in the U.S. and across the world. In 2018, it was estimated that 1.73 million people were diagnosed with cancer and 609,640 people died from the disease, according to the National Cancer Institute. Generally, for cancer cases, many patients receive treatments such as chemotherapy or radiotherapy to either make the cancer cells dormant or eliminate them. Notably, an emerging treatment for cancer is targeted therapy. While chemotherapy and targeted therapy both use drugs, targeted therapy is different because it specifically targets the cancer’s particular genes, proteins, and environment that aid in its spread and survival. However, chemotherapy can have serious side effects such as damaging cells in the bone marrow, hair follicles, and cells in the mouth, digestive tract, and reproductive system, leading to severe side effects. Nevertheless, biotechnology companies have aimed to develop innovative treatments that are much safer while maintaining their efficiency. In particular, therapeutic proteins have emerged because of its advantages over traditional treatments. For example, therapeutic proteins are a highly specific and complex set of functions that are less likely to interfere with normal biological processes and cause adverse effects, according to Creative Biolabs. Moreover, therapeutic proteins are well tolerated and less likely to cause immune responses. Additionally, certain protein-based drugs can control the growth and activity of immune cells and help boost your immune system to prevent cancer. “Today new avenues for cancer diagnostics and therapeutics present themselves. The choices include specific diagnostics, such as the rapidly evolving use of liquid biopsies that analyze cells and molecules spawned by the tumor and found in bodily fluids such as blood or urine, a more focused analysis of non-responders, the financial implications of future therapies, and an advocacy for a return to basic scientific research. The result of exploring these options will be a wider range of treatment choices for oncologists and a more positive outcome for patients,” said Steve Brozak, President of WBB Securities, LLC, an investment bank and research firm that specializes in the biotechnology, specialty pharmaceutical and medical device sectors.
For more information, please visit: Pressure Biosciences, Inc.
For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.